NCT00454636 - A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer. | Biotech Hunter

Enrollment

158

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions

Gastric Cancer

Interventions

DRUG

Cisplatin

80 mg/m2/day, intravenous (IV), every 3 weeks

DRUG

Capecitabine

1,000 mg/m2, oral, twice daily for 2 weeks, followed by 1 week of rest in each cycle

DRUG

Epirubicin

50 mg/m2/day, IV, every 3 weeks

DRUG

Cisplatin

60 mg/m2/day, IV, every 3 weeks

DRUG

Capecitabine

625 mg/m2, oral, twice daily per 3-week cycle

DRUG

Oxaliplatin

130 mg/m2/day, IV, every 3 weeks

DRUG

Docetaxel

60 mg/m2/day, IV, every 3 weeks

DRUG

Capecitabine

825 mg/m2, oral, twice daily for 2 weeks

Trial Locations (51)

11009

Cadiz

11407

Jerez de la Frontera

11510

Puerto Real

12002

Castellon

14004

Córdoba

15006

A Coruña

15009

A Coruña

15405

Ferrol

15706

Santiago de Compostela

17007

Girona

18003

Granada

18014

Granada

19002

Guadalajara

20080

Donostia / San Sebastian

22004

Huesca

22300

Barbastro

23007

Jaén

24071

León

25198

Lleida

26006

Logroño

27004

Lugo

28033

Madrid

28034

Madrid

28041

Madrid

28050

Madrid

28222

Madrid

28223

Madrid

28922

Alcorcón

28935

Madrid

30008

Murcia

31008

Navarra

Pamplona

32005

Ourense

33394

Gijón

34005

Palencia

36002

Pontevedra

36312

Vigo

37007

Salamanca

38320

San Cristóbal de La Laguna

41013

Seville

41014

Valencia

45004

Toledo

46026

Valencia

48013

Bilbao

50009

Zaragoza

03804

Alcoy

05071

Ávila

07014

Palma de Mallorca

07198

Palma de Mallorca

08916

Barcelona

09006

Burgos

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY